Experts hope a recent FDA approval for the first commercial at-home test for sexually transmitted diseases may help increase access to testing and curb rising rates
Among the more remarkable legacies of the COVID-19 pandemic is how quickly federal regulators, the health care industry and consumers moved to make at-home testing a reliable tool for managing a public health crisis. But that fast-track focus is missing from another, less publicized epidemic: an explosion in sexually transmitted diseases that can cause chronic pain and infertility among .
The popularity of at-home COVID tests has amplified calls from health researchers and diagnostic companies to make testing similarly routine for sexually transmitted diseases. But FDA guidelines are lagging.